These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 33668976)
1. Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease. Cheng YJ; Lin CH; Lane HY Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668976 [TBL] [Abstract][Full Text] [Related]
2. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease. Lin CH; Huang YJ; Lin CJ; Lane HY; Tsai GE Curr Pharm Des; 2014; 20(32):5169-79. PubMed ID: 24410566 [TBL] [Abstract][Full Text] [Related]
3. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors. Mota SI; Ferreira IL; Rego AC Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316 [TBL] [Abstract][Full Text] [Related]
5. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease. Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007 [TBL] [Abstract][Full Text] [Related]
6. Time-dependent effect of oligomeric amyloid-β (1-42)-induced hippocampal neurodegeneration in rat model of Alzheimer's disease. Karthick C; Nithiyanandan S; Essa MM; Guillemin GJ; Jayachandran SK; Anusuyadevi M Neurol Res; 2019 Feb; 41(2):139-150. PubMed ID: 30453864 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies. Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446 [TBL] [Abstract][Full Text] [Related]
8. Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues. Majdi A; Sadigh-Eteghad S; Rahigh Aghsan S; Farajdokht F; Vatandoust SM; Namvaran A; Mahmoudi J Rev Neurosci; 2020 May; 31(4):391-413. PubMed ID: 32017704 [TBL] [Abstract][Full Text] [Related]
9. The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis. Jasiecki J; Targońska M; Wasąg B Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670778 [TBL] [Abstract][Full Text] [Related]
10. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777 [TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs. Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884 [TBL] [Abstract][Full Text] [Related]
12. HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease. Mahady L; Nadeem M; Malek-Ahmadi M; Chen K; Perez SE; Mufson EJ Neuropathol Appl Neurobiol; 2019 Jun; 45(4):380-397. PubMed ID: 30252960 [TBL] [Abstract][Full Text] [Related]
14. Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer's Disease. Baracaldo-Santamaría D; Avendaño-Lopez SS; Ariza-Salamanca DF; Rodriguez-Giraldo M; Calderon-Ospina CA; González-Reyes RE; Nava-Mesa MO Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240413 [TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Auld DS; Kornecook TJ; Bastianetto S; Quirion R Prog Neurobiol; 2002 Oct; 68(3):209-45. PubMed ID: 12450488 [TBL] [Abstract][Full Text] [Related]
17. Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease. Ghosh S; Durgvanshi S; Agarwal S; Raghunath M; Sinha JK Curr Neuropharmacol; 2020; 18(9):883-903. PubMed ID: 32348223 [TBL] [Abstract][Full Text] [Related]
18. GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease. Nava-Mesa MO; Jiménez-Díaz L; Yajeya J; Navarro-Lopez JD Front Cell Neurosci; 2014; 8():167. PubMed ID: 24987334 [TBL] [Abstract][Full Text] [Related]
19. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Schaeffer EL; Gattaz WF Psychopharmacology (Berl); 2008 May; 198(1):1-27. PubMed ID: 18392810 [TBL] [Abstract][Full Text] [Related]
20. Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer's Disease Patients? Femminella GD; Leosco D; Ferrara N; Rengo G CNS Neurol Disord Drug Targets; 2016; 15(6):665-71. PubMed ID: 27189470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]